Intracranial Haemorrhage & Selective
Francisco J de Abajo, Hershel Jick, et al (Divison de Farmacoepidemiologia y Famacovigilancia Agencia Espanola del Medicamento, Madrid, Spain and the Boston Collaborative Drug Surveillance Program, Boston University Medical Centre, Lexington, Massachusetts, USA).
Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.
Br.J.Clin. Pharmacol, 50(1), July 2000, 43-47.
An increasing number of bleeding disorders have been reported with the use of selective serotonin reuptake inhibitors (SSRIs), including serious cases of intracranial haemorrhage. This study was performed to test the hypothesis of an increased risk of intracranial haemorrhage associated with the use of SSRIs.
Authors carried out a case-control study using a cohort of antidepressant users. UK based General Practice Research Database (GPRD) was the primary source of information. Subjects aged between 18 and 79 years who received a prescripiton for any antidepressant from January 1990 to October 1997 were included. Patients with any treatment that could be associated with an increased risk for intracranial haemorrhage were excluded.
Authors identified 65 cases of idiopathic intracranial haemorrhage and 254 matched controls. The results were not compatible with a major increased risk of intracranial haemorrhage among users of SSRIs or other antidepressants. However, smaller but still relevant increased risks cannot be ruled out.